Please login to the form below

Not currently logged in
Email:
Password:

AZ signs £11.5m bioinformatics deal with Manchester University

Five-year programme will focus on personalised health research
AZ

AstraZeneca and the University of Manchester have signed an £11.5m deal to harness clinical bioinformatics for personalised healthcare for patients.

The deal will see AZ invest a total of £11.5m to support clinical bioinformatics within the recently-established Centre for Cancer Biomarker Sciences at the Manchester Cancer Research Centre.

The research will be conducted in partnership with The Christie NHS Foundation Trust, which is at the forefront of experimental cancer medicine in the UK.

Mene Pangalos, executive VP of Innovative Medicines and Early Development at AstraZeneca, said: “This collaboration is exciting because it will eventually allow us to incorporate important data from clinical trials into a format that can be reviewed in real time by healthcare professionals and matched with information about cancer medicines.

“We will be able to modify clinical trial programmes accordingly and support clinicians to offer more accurate, personalised and rapid decision making to patients about their treatment.”

Projects will include new bioinformatics systems to capture and integrate clinical trial safety, efficacy, biomarker and drug distribution data in real time which will be presented in the form of graphs, easily interpretable by physicians, to help tailor treatment for patients.

Andrew Hughes of Manchester University's Institute of Cancer Sciences, said: “Patient insight is key to our understanding of new cancer drugs. The information we get from patients about their experiences of taking new drugs is key to shaping our risk and benefit assessment.

“AstraZeneca has long supported the UK science base and this latest collaboration with the Manchester Cancer Research Centre will enable the patients to share their insights with investigators and sponsors more effectively and efficiently than today, enabling a more informed assessment.”

The new collaboration builds on existing scientific ventures between AZ and The University of Manchester, which range from inflammatory research, lung cancer and new drug delivery systems. 

Article by
Nikhil Patel

9th September 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics